+

RS20070318A - Sterile formulations of modifier of immune response and processes - Google Patents

Sterile formulations of modifier of immune response and processes

Info

Publication number
RS20070318A
RS20070318A RSP-2007/0318A RSP20070318A RS20070318A RS 20070318 A RS20070318 A RS 20070318A RS P20070318 A RSP20070318 A RS P20070318A RS 20070318 A RS20070318 A RS 20070318A
Authority
RS
Serbia
Prior art keywords
imidazo
modifier
processes
immune response
sterile formulations
Prior art date
Application number
RSP-2007/0318A
Other languages
English (en)
Inventor
James D. Stoesz
Alexis S. Statham
Myhanh T. Truong
Original Assignee
Meda Ab.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38617896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS20070318(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Meda Ab., filed Critical Meda Ab.,
Publication of RS20070318A publication Critical patent/RS20070318A/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Opisana je farmaceutska kompozicija koja sadrži aktivnu supstancu izabranu iz grupe koju čine imikuimod (l-(2-metilpropil)-1H-imidazo[4,5-c]hinolin-4-amin), sotirimod (2-metil-l-(2-metilpropil)-1H-imidazo[4,5-c][l,5]naftiridin-4-amin) i rezikuimod (4-amino-α,α-dimetil-2-etoksimetil-1H-imidazo[4,5-c]hinolin-1-etanol) koja je stabilna prema sterilizaciji i pogodna za lokalnu primenu direktno na mesta na tkivu koja su probijena i koja je bila steriliziovana, i upakovana kompozicija koja je sterilizovana i postupke sterilizacije ovih jedinjenja.
RSP-2007/0318A 2006-07-31 2007-07-27 Sterile formulations of modifier of immune response and processes RS20070318A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82087606P 2006-07-31 2006-07-31

Publications (1)

Publication Number Publication Date
RS20070318A true RS20070318A (en) 2009-05-06

Family

ID=38617896

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20120043A RS52120B (sr) 2006-07-31 2007-07-19 Sterilne formulacije modifikatora imunog odgovora i postupci
RSP-2007/0318A RS20070318A (en) 2006-07-31 2007-07-27 Sterile formulations of modifier of immune response and processes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RS20120043A RS52120B (sr) 2006-07-31 2007-07-19 Sterilne formulacije modifikatora imunog odgovora i postupci

Country Status (24)

Country Link
US (1) US8124096B2 (sr)
EP (1) EP1891953B1 (sr)
AR (1) AR062121A1 (sr)
AT (1) ATE532511T1 (sr)
AU (1) AU2007279376B2 (sr)
CA (1) CA2659733A1 (sr)
CL (1) CL2007002228A1 (sr)
CY (1) CY1112264T1 (sr)
DK (1) DK1891953T3 (sr)
ES (1) ES2375744T3 (sr)
HR (1) HRP20120128T1 (sr)
IL (1) IL184652A (sr)
ME (1) MEP20608A (sr)
NO (1) NO338958B1 (sr)
PE (1) PE20080523A1 (sr)
PL (1) PL1891953T3 (sr)
PT (1) PT1891953E (sr)
RS (2) RS52120B (sr)
RU (1) RU2474425C2 (sr)
SI (1) SI1891953T1 (sr)
UA (1) UA93496C2 (sr)
UY (1) UY30513A1 (sr)
WO (1) WO2008016475A2 (sr)
ZA (1) ZA200900618B (sr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
RU2006105101A (ru) * 2003-08-27 2007-10-10 3М Инновейтив Пропертиз Компани (US) Арилокси и арилалкиленокси замещенные имидазохинолины
NZ546273A (en) 2003-10-03 2009-05-31 Coley Pharm Group Inc Alkoxy substituted imidazoquinolines
JP2007508305A (ja) 2003-10-03 2007-04-05 スリーエム イノベイティブ プロパティズ カンパニー ピラゾロピリジンおよびその類似物
CA2547020C (en) 2003-11-25 2014-03-25 3M Innovative Properties Company 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
AU2005322898B2 (en) 2004-12-30 2011-11-24 3M Innovative Properties Company Chiral fused (1,2)imidazo(4,5-c) ring compounds
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合[1,2]イミダゾ[4,5−c]環状化合物
AU2006338521A1 (en) 2005-02-09 2007-10-11 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
US20080318998A1 (en) * 2005-02-09 2008-12-25 Coley Pharmaceutical Group, Inc. Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines
AU2006216997A1 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
WO2006098852A2 (en) * 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
US8846710B2 (en) * 2005-02-23 2014-09-30 3M Innovative Properties Company Method of preferentially inducing the biosynthesis of interferon
US8158794B2 (en) * 2005-02-23 2012-04-17 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
WO2007030775A2 (en) 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of n-{2-[4-amino-2- (ethoxymethyl)-1h-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
ES2429170T3 (es) 2005-11-04 2013-11-13 3M Innovative Properties Company 1H-Imidazoquinolinas sustituidas con hidroxilo y alcoxilo y métodos
EP3085373A1 (en) 2006-02-22 2016-10-26 3M Innovative Properties Company Immune response modifier conjugates
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
WO2008030511A2 (en) * 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
GB0715428D0 (en) * 2007-08-08 2007-09-19 Imp Innovations Ltd Compositions and uses thereof
US20100160368A1 (en) * 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
DK2378876T3 (en) 2008-12-19 2019-03-11 Medicis Pharmaceutical Corp IMIQUIMOD FORMULATIONS WITH LOWER DOSAGE STRENGTH AND SHORT-TERM DOSAGE PLAN FOR TREATMENT OF ACTINIC KERATOSIS
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
PL2453747T3 (pl) 2009-07-13 2018-02-28 Medicis Pharmaceutical Corporation Preparaty imikwimodu o niższej mocy dawki i krótkie schematy dawkowania do leczenia brodawek narządów płciowych i okolic odbytu
BR112013003772A2 (pt) 2010-08-17 2016-08-02 3M Innovative Properties Co composições de compostos modificadores de resposta imunológica lipidadas, formulações e métodos
JP6415979B2 (ja) 2011-06-03 2018-10-31 スリーエム イノベイティブ プロパティズ カンパニー ヒドラジノ1h−イミダゾキノリン−4−アミン及びこれから調製された複合体
BR112013031028A2 (pt) 2011-06-03 2016-11-29 3M Innovative Properties Co conectores heterobifuncionais com segmentos de polietileno glicol e conjugados de modificadores de resposta imunológica feitos a partir deles
JP6335337B2 (ja) 2014-02-21 2018-05-30 アヴァディム・テクノロジーズ,インコーポレイテッド 尿道カテーテルの維持のための方法
US20160158393A1 (en) * 2014-02-21 2016-06-09 Avadim Technologies, Inc. Method for Improving Health Outcomes
MX2017006657A (es) 2014-11-19 2018-03-15 Avadim Tech Inc Método para la prevención y el tratamiento del acné.
GB201505347D0 (en) * 2015-03-27 2015-05-13 Salupont Consulting Ltd Sterilisation of s-nitrosothiols
JP7197244B2 (ja) 2017-12-20 2022-12-27 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤として使用するための分岐鎖連結基を有するアミド置換イミダゾ[4,5-c]キノリン化合物
CN109481674A (zh) * 2018-11-14 2019-03-19 大连亚维药业有限公司 一种生物无菌乳膏药物的生产方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US24906A (en) * 1859-07-26 Simeon goodfellow
IT610737A (sr) 1955-11-18 1900-01-01
US3700674A (en) 1969-04-30 1972-10-24 American Cyanamid Co 4-alkylamino-3-nitroquinolines
US4013665A (en) 1973-10-01 1977-03-22 Bristol-Myers Company Antiviral, substituted 1,3-dimethyl-1h-pyrazolo(3,4b)quinolines
US4052393A (en) 1975-11-03 1977-10-04 E. R. Squibb & Sons, Inc. 4-Substituted derivatives of pyrazolo [1,5-a]-quinoxaline-3-carboxylic acids and esters
US4197403A (en) 1977-01-07 1980-04-08 Westwood Pharmaceuticals Inc. 4-Aminosubstituted imidazo(1,2-A)quinoxalines
US4191767A (en) 1977-01-07 1980-03-04 Westwood Pharmaceuticals, Inc. Method for treating fungal infection in mammals with imidazo [1,2-a]quinoxalines
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4411893A (en) 1981-08-14 1983-10-25 Minnesota Mining And Manufacturing Company Topical medicament preparations
DE3364438D1 (en) 1982-10-18 1986-08-14 Pfizer Triazoloquinoxalines as antidepressants and antifatigue agents
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
CA1248450A (en) 1984-04-05 1989-01-10 Kazuo Kigasawa Soft patch
EP0187705A3 (en) 1985-01-08 1988-05-11 Norwich Eaton Pharmaceuticals, Inc. Imidazo(4,5-f)quinolines useful as immunomodulating agents
US4751087A (en) 1985-04-19 1988-06-14 Riker Laboratories, Inc. Transdermal nitroglycerin delivery system
US4908389A (en) 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US4746515A (en) 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
EP0375689B1 (en) 1987-06-01 1992-08-12 Warner-Lambert Company A pharmaceutical composition adapted for transdermal delivery of an opoid drug.
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
ES2186034T3 (es) 1991-03-01 2003-05-01 Minnesota Mining & Mfg Intermedios para la preparacion de 1h-imidazo(4,5-c)quinolin-4-aminas 1-sustituidas, 2-sustituidas.
ATE195735T1 (de) 1993-07-15 2000-09-15 Minnesota Mining & Mfg Imidazo (4,5-c)pyridin-4-amine
KR100518903B1 (ko) 1996-10-25 2005-10-06 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 Th2 매개 질병 및 관련 질병의 치료용 면역 반응 조절 화합물
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
EP0877089A1 (en) 1997-05-07 1998-11-11 Gist-Brocades B.V. HMG-CoA reductase inhibitor preparation process
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
SI1512685T1 (sl) 1997-12-11 2006-12-31 Minnesota Mining & Mfg Imidazonaftiridini in njihova uporaba v induciranju biosinteze citokina
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
IL144028A0 (en) 1999-01-08 2002-04-21 3M Innovative Properties Co Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
RU2143900C1 (ru) * 1999-03-31 2000-01-10 Институт цитологии и генетики СО РАН Способ получения изониазида пролонгированного действия
DE19941509A1 (de) 1999-08-31 2001-03-29 Interconnectron Ges Fuer Ind S Rundsteckverbinder zur Herstellung elektrischer Leitungsverbindungen
US6464937B2 (en) * 2000-11-01 2002-10-15 Pml Microbiologicals, Inc. Ultrapure sterilization of microbiological test media by electron beam irradiation
US20030026794A1 (en) 2001-07-31 2003-02-06 Howard Fein Selective enzyme treatment of skin conditions
CN100473384C (zh) 2001-11-29 2009-04-01 3M创新有限公司 包括免疫反应改性剂的药物制剂
US20060183767A1 (en) 2003-01-06 2006-08-17 Eugene Mandrea Methods of stimulating immune response in certain individuals
MXPA05009694A (es) 2003-03-13 2005-10-20 3M Innovative Properties Co Metodos para mejorar la calidad de la piel.
AU2004268665A1 (en) 2003-09-02 2005-03-10 3M Innovative Properties Company Methods related to the treatment of mucosal associated conditions
US20050175630A1 (en) 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
EP1602365A1 (en) * 2004-03-03 2005-12-07 Switch Biotech Aktiengesellschaft Pharmaceutical composition for topical use in form of xerogels or films and methods for production
US20050201959A1 (en) 2004-03-11 2005-09-15 Vvii Newco 2003, Inc. Methods and compositions for altering skin coloration
WO2006029223A2 (en) 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
US8080560B2 (en) 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US8436176B2 (en) 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine

Also Published As

Publication number Publication date
ES2375744T3 (es) 2012-03-05
CY1112264T1 (el) 2015-12-09
NO20073913L (no) 2008-02-01
SI1891953T1 (sl) 2012-05-31
RU2007129104A (ru) 2009-02-10
UY30513A1 (es) 2008-02-29
ZA200900618B (en) 2010-03-31
RS52120B (sr) 2012-08-31
AU2007279376A1 (en) 2008-02-07
PT1891953E (pt) 2012-01-24
US8124096B2 (en) 2012-02-28
MEP20608A (en) 2010-06-10
IL184652A (en) 2014-02-27
IL184652A0 (en) 2008-01-20
ATE532511T1 (de) 2011-11-15
UA93496C2 (uk) 2011-02-25
WO2008016475A3 (en) 2008-11-20
NO338958B1 (no) 2016-11-07
RU2474425C2 (ru) 2013-02-10
HRP20120128T1 (hr) 2012-03-31
PE20080523A1 (es) 2008-07-13
AR062121A1 (es) 2008-10-15
DK1891953T3 (da) 2012-02-27
PL1891953T3 (pl) 2012-04-30
US20100096287A1 (en) 2010-04-22
EP1891953A1 (en) 2008-02-27
EP1891953B1 (en) 2011-11-09
AU2007279376B2 (en) 2012-09-06
WO2008016475A2 (en) 2008-02-07
CA2659733A1 (en) 2008-02-07
CL2007002228A1 (es) 2008-01-18

Similar Documents

Publication Publication Date Title
RS20070318A (en) Sterile formulations of modifier of immune response and processes
MX391854B (es) Formulaciones farmaceuticas que contienen hidrato de propilenglicol de dapagliflozina
CL2007002095A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composicion empacada; metodo para esterilizarla; util para cicatrizar tejido donde la dermis se ha desgarrado.
TW200517150A (en) Mist sterilization system
PL1888127T3 (pl) Sposób sterylizacji urządzenia medycznego posiadającego powłokę hydrofilową
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2005067986A8 (en) Sterilization system and device
UA94928C2 (en) Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
SG135189A1 (en) High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
UY25192A1 (es) Formulación medicamentosa con liberación controlada de sustancia activa
NO20071485L (no) Kjemiske substanser.
WO2004091591A3 (fr) Composition nutritionnelle ou therapeutique contenant le compose oleurofeine ou l'un de ses derives
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
GB2446341A (en) Method and system for transdermal drug delivery
AR064152A1 (es) Derivados de quinolina antibacterianos,composiciones farmaceuticas que los contienen y metodo de preparacion.
CY1111059T1 (el) Φωτοσταθερη φαρμακευτικη συνθεση η οποια περιεχει βριβουδινη για την αγωγη της ερπητικης κερατιτιδας
IL195062A0 (en) Process for the preparation of solid sterile active pharmaceutical ingredient
UA87291C2 (ru) Пероральное пленкообразное лекарственное средство дезоксипеганина и способ его применения
EP1603595A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE
WO2008049915A3 (de) Verfahren zum sterilisieren eines folienbehälters
EP1852119A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING A PHENOXAZINE COMPOUND AS AN ACTIVE SUBSTANCE
MXPA05005460A (es) Contraste de ultrasonido que usa xantenos halogenados.
PT1889629E (pt) Formulação estável compreendendo uma associação de um fármaco sensível à humidade e de um segundo fármaco e processo para o seu fabrico
MY140242A (en) BICYCLIC 6-ALKYLIDENE-PENEMS AS ß-LACTAMASES INHIBITORS
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载